Created On: 2020-07-15
Record Count: 12
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7344
RMS: RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).
RPC1063 for the treatment of UC: IBD is comprised of two chronic, autoimmune, GI inflammatory disorders: UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.
IPSCIO Record ID: 26261
IPSCIO Record ID: 210693
IPSCIO Record ID: 264191
ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur.
IPSCIO Record ID: 233469
Balsalazide means 5-[4(2-Carboxyethelcarbamoyl)-phenylazo] – salicylic acid disodium salt dihydrate.
Products means products incorporating Balsalazide, whether or not such products are covered by the Patent Rights, or any other material whose manufacture, use or sale by an unlicensed third party would constitute an infringement of any Valid Claim included within the Patent Rights.
First marketed product, Colazal, was the first new molecular entity approved in 10 years by the FDA for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the FDA for this indication in seven years. Ulcerative colitis is a chronic form of inflammatory bowel disease characterized by inflammation of the lining of the colon. Symptoms of active ulcerative colitis include rectal bleeding, abdominal pain, increased stool frequency, loss of appetite, fever and weight loss.
IPSCIO Record ID: 263902
The name of the product is SalofalkÂ® 500 mg, Granu-StixÂ®. Salofalk Granu-Stix delivers the therapeutically active antiinflammatory agent mesalamine (5-aminosalicylic acid or 5-ASA) to the distal ileum and colon by means of dual-release granules.
The patents include Pellet formulation for the treatment of the intestinal tract, and, Pellet-type formulation intended for treating the intestinal tract.
Ulcerative colitis (UC) is a disease that affects your large intestine, or colon. It causes irritation and swelling called inflammation. … UC is a type of inflammatory bowel disease, but it's different from other diseases with similar symptoms, like Crohn's disease or irritable bowel syndrome.
IPSCIO Record ID: 26279
Opioid analgesics provide pain relief by stimulating opioid receptors located in the central nervous system. There are, however, opioid receptors throughout the body, including the GI tract. By binding to the receptors in the GI tract, opioid analgesics can slow gut motility and disrupt normal GI function that allows for the passage, absorption and excretion of ingested solid materials. This disruption can cause patients to experience significant discomfort and abdominal pain and may result in their reducing or eliminating their pain medication.
Entereg is a small molecule, mu-opioid receptor antagonist intended to block the adverse side effects of opioid analgesics on the GI tract without affecting analgesia. We are developing Entereg for both acute and chronic conditions.
IPSCIO Record ID: 240497
Primary Progressive Multiple Sclerosis, MS (PPMS) is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.
IPSCIO Record ID: 29002
IPSCIO Record ID: 26622
IPSCIO Record ID: 797
The grant of each License hereunder includes the right to grant subLicenses to Related Companies.
Trademarks mean Feldetrexâ„¢, including US Trademark Application No. 77/601,101 and any identical marks later filed in countries other than the United States of America.
Feldetrexâ„¢ drug is a proprietary combination of generic medications which is believed to reduce the symptomatology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury.
Multiple Sclerosis is a chronic, progressive illness that affects the nerves in the brain, spinal cord, and other parts of the central nervous system.
Fibromyalgia (FM or FMS) is characterized by chronic widespread pain and allodynia (a heightened and painful response to pressure). Its exact cause is unknown but is believed to involve psychological, genetic, neurobiological and environmental factors.
Licensee shall prominently use the Trademark on Licensed Products.
IPSCIO Record ID: 26724
Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patientâ€™s nerve tissue.